Larvol Delta - CLARITYCRP-A-Study-of-Clazakizumab-LY5724886-in-Adults-With-Elevated-hsCRP-and-at-Increased-Risk-for-Cardiovascular-Event

clazakizumab (CSL300) - CSL Behring, Eli Lilly

http://clinicaltrials.gov/ct2/show/NCT07783802

Sep 22, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next